Global Leading Market Research Publisher QYResearch announces the release of its latest report “PDRN Supplements – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global PDRN Supplements market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for PDRN Supplements was estimated to be worth US$ 440 million in 2025 and is projected to reach US$ 756 million, growing at a CAGR of 8.2% from 2026 to 2032.
In 2024, global PDRN supplement production reached approximately 125 metric tons,with an average global market price of around US$ 3,200 per kilogram.PDRN (Polydeoxyribonucleotide) supplements are derived from purified DNA fragments, typically extracted from salmon or trout sperm. They are used in nutraceuticals and cosmetics for their potential regenerative, anti-inflammatory, and skin-repairing properties.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6095330/pdrn-supplements
1. Industry Pain Points and the Shift Toward DNA-Based Regenerative Supplements
Chronic inflammation, tissue damage (wounds, osteoarthritis), and skin aging require safe, effective regenerative therapies. Traditional treatments (NSAIDs, corticosteroids) have side effects (GI bleeding, immunosuppression). PDRN supplements address this with polydeoxyribonucleotide—purified DNA fragments (salmon/trout sperm) that promote tissue regeneration via A2A adenosine receptor activation, stimulating fibroblast proliferation, collagen synthesis, and angiogenesis. For clinicians and patients, PDRN offers tissue regeneration, anti-inflammatory therapy, and wound healing with a favorable safety profile.
2. Market Size, Production Volume, and Growth Trajectory (2024–2032)
According to QYResearch, the global PDRN supplements market was valued at US$ 440 million in 2025 and is projected to reach US$ 756 million by 2032, growing at a CAGR of 8.2%. In 2024, global production reached approximately 125 metric tons with an average selling price of US$ 3,200 per kilogram. Market growth is driven by three factors: expansion of aesthetic dermatology (skin rejuvenation, hair restoration), sports medicine (tendinopathy, osteoarthritis), and chronic wound care (diabetic ulcers, pressure sores).
3. Six-Month Industry Update (October 2025–March 2026)
Recent market intelligence reveals four notable developments:
- Osteoarthritis clinical trials: PDRN injections (intra-articular) for knee OA showed pain reduction (VAS -30 mm) and functional improvement (WOMAC) comparable to hyaluronic acid, with longer duration (6 months). Sports medicine segment grew 15% year-over-year.
- Diabetic ulcer healing: Topical PDRN gel accelerated wound closure (2.5 cm²/week vs. 1.0 cm²/week for standard care) in Phase 2 trial. Wound care segment grew 20% in 2025.
- Aesthetic dermatology expansion: Injectable PDRN (“salmon DNA”) for skin rejuvenation (fine lines, elasticity, hydration) gained 25% market share in Asia-Pacific (Korea, China, Japan).
- Oral supplement launch: New oral PDRN capsules (Euglena, PharmaResearch) for systemic anti-inflammatory and tissue repair effects, expanding beyond injectable/topical routes.
4. Competitive Landscape and Key Suppliers
The market includes Korean pharmaceutical leaders and European specialists:
- Caregen Co., Ltd. (Korea), Daehan New Pharm Co., Ltd. (Korea), DongKook Pharmaceutical Co., Ltd. (Korea), Euglena Co., Ltd. (Japan), Ildong Pharmaceutical Co., Ltd. (Korea), Mastelli Srl (Italy – Placentex), PharmaResearch Products Co., Ltd. (Korea), Rejuven Co., Ltd. (Korea), Salmon DNA Korea Co., Ltd. (Korea), Shin Poong Pharm Co., Ltd. (Korea).
Competition centers on three axes: source species (salmon vs. trout), molecular weight (kDa), and delivery route (injectable, topical, oral).
5. Segment-by-Segment Analysis: Type and Application
By Source
- Salmon-derived: Largest segment (~70% of market). Higher purity, standardized molecular weight (50-1,500 kDa). Preferred for injectable and topical formulations.
- Trout-derived: (~30% of market). Lower cost, emerging for oral supplements.
By Application
- Aesthetic Dermatology: Largest segment (~45% of market). Skin rejuvenation, hair restoration, scar reduction. Fastest-growing segment (CAGR 9%).
- Clinical Nutrition: (~25% of market). Oral supplements for systemic anti-inflammatory, tissue repair.
- Sports Medicine: (~15% of market). Tendinopathy (Achilles, patellar), osteoarthritis, muscle recovery.
- Others: Wound care, post-surgical healing. ~15% of market.
User case – Knee osteoarthritis (intra-articular PDRN) : A 65-year-old patient with knee OA (Kellgren-Lawrence grade 3) received 3 weekly PDRN injections (Mastelli Placentex, 2 mL). VAS pain score decreased from 70 mm to 30 mm at 1 month, maintained at 6 months (35 mm). WOMAC function score improved 50%. No adverse events. Patient avoided knee replacement for 2+ years.
6. Exclusive Insight: PDRN Mechanism and Clinical Applications
| Mechanism | Effect | Clinical Application |
|---|---|---|
| A2A adenosine receptor activation | Anti-inflammatory (↓IL-1β, TNF-α, COX-2) | Osteoarthritis, tendinopathy |
| Fibroblast proliferation | Collagen synthesis (type I, III), tissue regeneration | Wound healing, skin rejuvenation |
| VEGF upregulation | Angiogenesis, improved blood flow | Diabetic ulcers, ischemic wounds |
| Growth factor stimulation | FGF, EGF, IGF-1 | Hair restoration, tendon repair |
| NLRP3 inflammasome inhibition | Reduced pyroptosis, cell death | Chronic inflammation |
Technical challenge: Standardizing molecular weight for consistent bioactivity. PDRN fragments (50-1,500 kDa) have different receptor affinity. Optimal range: 50-500 kDa for anti-inflammatory effect; 500-1,500 kDa for tissue regeneration. Manufacturers (Caregen, DongKook, Mastelli) use proprietary hydrolysis and chromatography for consistent MW distribution.
User case – Tendinopathy (Achilles) : A runner with chronic Achilles tendinopathy (6 months) received 3 weekly PDRN injections (DongKook, 2 mL peritendinous). VAS pain decreased from 65 mm to 20 mm at 3 months. Return to running at 6 months (5 km without pain). Ultrasound showed reduced tendon thickness (8 mm → 6 mm) and neovascularization.
7. Regional Outlook and Strategic Recommendations
- Asia-Pacific: Largest and fastest-growing region (50% share, CAGR 9%). Korea (Caregen, Daehan, DongKook, Ildong, PharmaResearch, Rejuven, Salmon DNA Korea, Shin Poong), Japan (Euglena). Strong aesthetic dermatology and sports medicine adoption.
- Europe: Second-largest (25% share, CAGR 7.5%). Italy (Mastelli). Established clinical use (Placentex for wound healing).
- North America: Growing market (15% share, CAGR 8%). Emerging interest in PDRN for sports medicine and aesthetics (off-label).
- Rest of World: Latin America, Middle East. Smaller but growing.
8. Conclusion
The PDRN supplements market is positioned for strong growth through 2032, driven by aesthetic dermatology, sports medicine, and wound care. Stakeholders—from pharmaceutical manufacturers to clinicians—should prioritize injectable PDRN for osteoarthritis and tendinopathy, topical formulations for wound healing and skin rejuvenation, and oral supplements for systemic anti-inflammatory effects. By enabling tissue regeneration and anti-inflammatory therapy, PDRN supplements offer a safe, effective alternative to traditional treatments.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
